Global Liquid Biopsy Market is estimated to witness a lucrative CAGR of 17% by 2026

Liquid Biopsy is a procedure of sampling and analyzing non-solid biological tissues (such as blood and others), for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders. The sampling procedures are minimally invasive, quick and incur minimal patient pain and risk. Liquid Biopsy also helps in the early diagnosis of various types of cancers such as breast cancer, non-small cell lung carcinoma, lymphomas, head and neck cancer, and leukemia.

Advent of Advanced Technologies for Liquid Biopsy Drives the Global Market

Liquid biopsy is an emerging technology and has the potential to revolutionize early cancer detection by analyzing available ctDNA for specific mutation profiles, fragmentation patterns, and methylation signatures. The significant developments in a digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies has led to a significant reduction in sequencing cost with the improvement in the accuracy of liquid biopsy. Further advancements in technology are expected to trigger the growth of the market in the coming years.

Growing Adoption of Circulating Biomarkers for Early Detection & Screening of Cancer

Currently,  circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are the most commonly used liquid biopsy-derived biomarkers. In the recent years, CTCs have gained immense significance in detecting tumors, replacing invasive tissue biopsies not only due to their ease in sampling but also in providing data regarding tumor conditions in a ‘real-time’ manner. CTCs can also be used in vivo for the generation of patient-derived tumor models that assist in treatments.

“Liquid Biopsy is a dynamic and continuously evolving field. Technological advancements directed towards faster and more convenient diagnosis will drive the market. Liquid biopsies could be a game-changer in cancer testing.” - Head of Diagnostic Biomarkers, Liquid Biopsy Company, United States

North America Leads the Adoption of Liquid Biopsy Market

From a geographical perspective, North America holds the largest market share of the liquid biopsy market. The rising prevalence of cancer cases among the population in US, increased adoption of liquid biopsy for the diagnosis of cancer, higher patient preference for non-invasive diagnosis and monitoring and the presence of key players in this region are some of the key factors driving the market growth.

Competitive Landscape Analysis: Global Liquid Biopsy Market

Some of the top players operating in the global liquid biopsy market are F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Guardant Health Inc., MDxHealth SA, and Illumina Inc., among others.

Companies Adopting Inorganic Growth Strategies to Increase their Market Share

Players operating in the liquid biopsy market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner higher market share. For instance, In May 2022,  Guardant Health, Inc. a leading precision oncology company, announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC).

Interest of Private Equity Firms in Liquid Biopsy Market

To leverage upcoming growth opportunities in the global liquid biopsy market, private equity firms are making investments in potentially high-growth areas/companies in this space. For instance, In May 2022, BioMarks Diagnostics secured $1.5 million from a private financing round to accelerate the commercialization of its liquid biopsy technology.

Get Detailed Research Insights on Liquid Biopsy Market @ https://meditechinsights.com/liquid-biopsy-market/

Comments

Post a Comment

Popular posts from this blog

Global HPV Testing and PAP Test Market is slated to grow at a lucrative CAGR of 12 to 15 % by 2027 – Growing Revolution for the Prevention of Cervical Cancer

Cervical cancer is a malignant tumor which starts in the cells of the cervix, the lowermost part of the uterus. Cervical cancer begins when the cells on its surface transforms into precancerous cells. If not destroyed, these abnormal cells may turn into harmful cancer cells and spread in the cervix and surrounding areas. Cervical cancer screening involves HPV and PAP tests , which can identify HPV infection or pre-cancerous lesions at an early stage and if correct treatment is offered at the right time then the cancer can be prevented. Impact of  Covid-19 on  the Global HPV Testing and PAP Test Market Covid-19 pandemic had impacted the healthcare market in many ways. During Covid pandemic, due to strict social-distancing norms in hospitals, there was a delay in many diagnostic examinations and procedures. The delay in the cancer screening services due to the lack of skilled healthcare staff and disruption in the supply chain of testing kits across the world had led to a severe impact o
Read more

Global Ambulatory Surgical Center (ASC) Software Market is Poised to Grow at a CAGR of 10% by 2027

Ambulatory Surgical Care is a medical care offered in the outpatient setting and does not need any hospital admission. Ambulatory Surgical Center or ASCs—are health care facilities focused on offering same-day surgical care, including diagnostic and preventive procedures. ASCs have transformed the outpatient experience by offering a convenient alternative to hospital-based outpatient procedures. Common procedures performed in ASCs are cataract surgery, gallbladder removal, tonsillectomy, endoscopy, colonoscopy, arthroscopic or orthopedic procedures, and cardiac procedures. Owing to their various cost benefits and convenience, the volume of procedures performed at ASCs is rising and ASC software is likely to play a major role in these settings by easing the day to day operations by preparing staff and patients for pre-op and post-op tasks. Rising Investments in Ambulatory Surgical Center  from Healthcare Companies Shows a Huge Growth Potential for Ambulatory Surgical Center Software Ma
Read more

Global Drug Discovery Software market valued at $2 billion in 2020, is projected to grow at a healthy CAGR of 14% to reach $3.5 billion by 2025

The global drug discovery software market (such as ligand-based design, structure-based design, LIMS, ELN) is driven by the increasing R&D spend and pipeline, expanding scope and scale, increasing stringency of testing and regulations, growing number and size of biotechs, need for increasing cost efficiencies and reducing time to market, and move towards web/cloud-based software. Global Drug Discovery Software Market – Niche but Fast-Growing Market The worldwide drug discovery software market is niche and growing rapidly, driven by the rising pressure on the pharma and biotech companies to cut costs in the research and preclinical stage of drug development, reduce timelines and improve transparency through deep learning software tools. “ Large players present in this segment are trying to consolidate the market by becoming a one stop shop. Moreover, companies are also considering to combine their solutions with bioinformatics and LIMS tools to have a competitive edge .” - Exe
Read more